CALPAIN-3 DEFICIENCY LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A

Clinical trials for CALPAIN-3 DEFICIENCY LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A explained in plain language.

Never miss a new study

Get alerted when new CALPAIN-3 DEFICIENCY LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A trials appear

Sign up with your email to follow new studies for CALPAIN-3 DEFICIENCY LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Paving the way: new study aims to sharpen tools for LGMD R1 trials

Knowledge-focused Ongoing

This 24-month observational study follows 100 people aged 12–50 with Limb Girdle Muscular Dystrophy type R1 (LGMD R1). Researchers will test whether a motor function scale called NSAD and muscle fat measurements from MRI can reliably track disease progression. The goal is to vali…

Matched conditions: CALPAIN-3 DEFICIENCY LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A

Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused

Last updated Jun 27, 2026 13:07 UTC

CALPAIN-3 DEFICIENCY LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A

Get alerted when new CALPAIN-3 DEFICIENCY LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A trials appear

Paving the way: new study aims to sharpen tools for LGMD R1 trials